Targeting nanomaterials: future drugs for cancer chemotherapy
Yibo Zhang, Tianfeng ChenDepartment of Chemistry, Jinan University, Guangzhou, ChinaConcerning the recent articles published in your journal on multifunctional nanosystem for cancer chemotherapy.1 It should be an admirable approach to kill cancer cells, with the least side effects on normal tissues...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/dfdd27ab71f649f59b0b7eb767830f24 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:dfdd27ab71f649f59b0b7eb767830f24 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dfdd27ab71f649f59b0b7eb767830f242021-12-02T07:21:25ZTargeting nanomaterials: future drugs for cancer chemotherapy1176-91141178-2013https://doaj.org/article/dfdd27ab71f649f59b0b7eb767830f242012-10-01T00:00:00Zhttp://www.dovepress.com/targeting-nanomaterials-future-drugs-for-cancer-chemotherapy-a11230https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Yibo Zhang, Tianfeng ChenDepartment of Chemistry, Jinan University, Guangzhou, ChinaConcerning the recent articles published in your journal on multifunctional nanosystem for cancer chemotherapy.1 It should be an admirable approach to kill cancer cells, with the least side effects on normal tissues and cells. During the past few decades, various chemotherapeutic agents, such as cyclophosphamide, fluorouracil, platinum-based compounds, anthracycline, hydroxycamptothecin and paclitaxel, have been designed and proved to be effective toward cancer cells. However, regrettably, these drugs are non-targeted to cancer, and thus serious side effects to normal cells or tissues are unavoidable.2 Therefore, new drugs with selective cytotoxicity become an important research focus in cancer chemotherapy. Another obstacle for chemotherapy is the multidrug resistance. Actually, several targeted drugs such as RTK inhibitors, FTase inhibitors, tumor angiogenesis inhibitors, campath, avastin and erbitux, have been commercialized and widely used clinically.3 However, drug resistance seriously limited their anticancer efficacy. Nanotechnology-based approaches are anticipated to provide a new breakthrough for targeting cancer cells and bypassing their multidrug resistance.4View original paper by Wang and colleagues.Zhang YChen TDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 5283-5286 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Zhang Y Chen T Targeting nanomaterials: future drugs for cancer chemotherapy |
| description |
Yibo Zhang, Tianfeng ChenDepartment of Chemistry, Jinan University, Guangzhou, ChinaConcerning the recent articles published in your journal on multifunctional nanosystem for cancer chemotherapy.1 It should be an admirable approach to kill cancer cells, with the least side effects on normal tissues and cells. During the past few decades, various chemotherapeutic agents, such as cyclophosphamide, fluorouracil, platinum-based compounds, anthracycline, hydroxycamptothecin and paclitaxel, have been designed and proved to be effective toward cancer cells. However, regrettably, these drugs are non-targeted to cancer, and thus serious side effects to normal cells or tissues are unavoidable.2 Therefore, new drugs with selective cytotoxicity become an important research focus in cancer chemotherapy. Another obstacle for chemotherapy is the multidrug resistance. Actually, several targeted drugs such as RTK inhibitors, FTase inhibitors, tumor angiogenesis inhibitors, campath, avastin and erbitux, have been commercialized and widely used clinically.3 However, drug resistance seriously limited their anticancer efficacy. Nanotechnology-based approaches are anticipated to provide a new breakthrough for targeting cancer cells and bypassing their multidrug resistance.4View original paper by Wang and colleagues. |
| format |
article |
| author |
Zhang Y Chen T |
| author_facet |
Zhang Y Chen T |
| author_sort |
Zhang Y |
| title |
Targeting nanomaterials: future drugs for cancer chemotherapy |
| title_short |
Targeting nanomaterials: future drugs for cancer chemotherapy |
| title_full |
Targeting nanomaterials: future drugs for cancer chemotherapy |
| title_fullStr |
Targeting nanomaterials: future drugs for cancer chemotherapy |
| title_full_unstemmed |
Targeting nanomaterials: future drugs for cancer chemotherapy |
| title_sort |
targeting nanomaterials: future drugs for cancer chemotherapy |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/dfdd27ab71f649f59b0b7eb767830f24 |
| work_keys_str_mv |
AT zhangy targetingnanomaterialsfuturedrugsforcancerchemotherapy AT chent targetingnanomaterialsfuturedrugsforcancerchemotherapy |
| _version_ |
1718399487428263936 |